The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

Blocking a protein that imports lactic acid, a metabolic byproduct of cancer cells, reinvigorated exhausted T cells and led to improved tumor control in mouse models of cancer, according to a new ...

The global burden of digestive tract tumors is profound, with these cancers accounting for nearly half of all malignant ...

Persister cells (PCs) and cancer stem cells (CSCs), which exhibit heightened ... Emerging immunotherapies, like PD-1 and PD-L1 inhibitors, have also been linked to ferroptosis induction. PD-L1 ...

Researchers from the National Defense Medical Center in Taiwan have identified an increased risk of psoriasis in patients ...

The test improved prediction of patient benefit from anti-PD-1 immune checkpoint inhibitors (ICIs) as a monotherapy and with ...

BPT958, a bifunctional PD-1 immunoconjugate with a masked IL-2 payload designed to be processed specifically in the tumor microenvironment ...

Chavez, MD, discusses the efficacy of immunotherapy for the potential treatment of extensive-stage small cell lung cancers.

Programmed cell death-1, or PD-1, has become a headline-grabbing molecule best known for its role in cancer immunotherapies ...

IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti-PD ...

However, "ICIs block inhibitory pathways, such as PD-1/PD-L1 and CTLA-4, which cancer cells use to evade the immune system, thereby leading to the reactivation of T cells," they wrote. "This may ...

NEW YORK – Cel-Sci on Thursday said the US Food and Drug Administration agreed with its plan to select head and neck cancer patients with low PD-L1 tumor expression in a confirmatory registrational ...